^
Association details:
| Biomarker: | CPEB1 underexpression |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | 5-fluorouracil (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Low CPEB1 levels may predict the benefit of 5-fluorouracil treatment in patients with colon or stomach adenocarcinoma
Published date:
09/13/2022
Excerpt:
Our results indicate that the level of CPEB1 expression may be valuable for predicting the benefit of 5-FU treatment for patients with colon and stomach adenocarcinomas. We therefore propose that low CPEB1 expression may represent a novel biomarker for personalized 5-FU therapy.
DOI:
10.21037/jgo-22-561
